Pierre-Emmanuel Brachet

Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol

Paul Lesueur, Justine Lequesne, Jean‐Michel Grellard et al. · BMC Cancer · 2019 · 116 citations · Full text

Medicine, Oncology, Pharmacology +14

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

Jean‐Emmanuel Kurtz, Éric Pujade-Lauraine, Ana Oaknin et al. · Journal of Clinical Oncology · 2023 · 103 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer

Claire Falandry, Frédérique Rousseau, Marie‐Ange Mouret‐Reynier et al. · JAMA Oncology · 2021 · 81 citations · Full text

Medicine, Gynecology, Oncology +17

A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI – GINECO study

Florence Joly, Michel Fabbro, Philippe Follana et al. · Gynecologic Oncology · 2022 · 33 citations

Medicine, Gynecology, Oncology +16

Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era

Gwénaëlle Gravis, Brice Chanez, Lisa Derosa et al. · Urologic Oncology Seminars and Original Investigations · 2015 · 31 citations

Medicine, Cancer Biology, Oncology +16